No Data
No Data
Eli Lilly's Stock Plunges as Investors Eye Obesity-drug Competition
By Eleanor Laise 'Vast' weight-loss drug pipeline keeps Lilly in a strong position as field gets crowded, analysts say Eli Lilly & Co.'s stock was on pace for its worst day in about three years
Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk
By Eleanor Laise A selloff for Structure Therapeutics and other weight-loss drugmakers' stocks is overdone, analysts say Shares of weight-loss drugmakers including Eli Lilly & Co., Novo Nordisk A/S
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, Altimmune (NASDAQ:ALT) shareholders have done very
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating
B.Riley Financial analyst Mayank Mamtani maintains $Altimmune(ALT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 27.8% and a total average return of -16.5% over
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
No Data
Chili Dog : So see how many
DazzyJazzy : buying ang waiting